Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 87.55
+3.65 (4.35%)
Jun 18, 2026, 4:08 PM HKT
Akeso Revenue
In the year 2025, Akeso had annual revenue of 3.06B CNY with 43.90% growth. Akeso had revenue of 1.64B in the half year ending December 31, 2025, with 93.64% growth.
Revenue
3.06B CNY
Revenue Growth
+43.90%
P/S Ratio
23.71
Revenue / Employee
812.62K CNY
Employees
3,761
Market Cap
80.65B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 44.73B |
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.84B |
Akeso News
- 3 days ago - Akeso's Ligufalimab Combination Shows Deep Responses And Survival Benefit In Frontline AML - Nasdaq
- 3 days ago - Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 - PRNewsWire
- 8 days ago - Akeso's Gumokimab Gets NMPA Nod For Treating Plaque Psoriasis - Nasdaq
- 9 days ago - Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio - PRNewsWire
- 19 days ago - An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. - Market Watch
- 19 days ago - Akeso lung cancer drug shines in trials, boosting hopes in US$20b market - South China Morning Post
- 19 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 20 days ago - Akeso (AKESF) Reports Positive Phase 3 Results for Lung Cancer Treatment - GuruFocus